CoChat

Development of hyperandrogenism during treatment with insulin‐like growth factor‐I (IGF‐I) in female patients with Laron syndrome

Open access
Klinger, Anin, Silbergeld, Eshet, Laron · 1998 · Clinical Endocrinology
Cited by 85

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Patients with Laron syndrome (LS) can now be treated with recombinant IGF‐I. We describe the development of androgenization during IGF‐I treatment of female LS patients. PATIENTS: Six female patients with LS—two clinically prepubertal (11.6 and 13.8 years of age) and four young adults (30 to 39 years old)—underwent long‐term replacement treatment with recombinant IGF‐I. The daily doses were 150 μg/kg/day by subcutaneous (s.c.) injection in the girls and 120 μg/kg/day in the adult women. METHODS: Testosterone, Δ4‐androstenedione, LH, FSH, insulin and IGF‐I were determined by radioimmunoassay. Blood samples were obtained after an overnight fast before the IGF‐I injection. Serum IGF‐I was also determined 4 hours after the s.c. injections. RESULTS: During IGF‐I treatment, four out of the six patients (two girls and two adults) developed progressive clinical symptoms and signs of hyperandrogenism (oligo/amenorrhoea and acne). Laboratory determinations showed a significant elevation in serum testosterone, Δ4‐androstenedione and LH/FSH ratio. The hyperandrogenism occurred concomitantly with an increase in IGF‐I serum and a decrease in serum insulin concentrations. Reduction in IGF‐I dose or interruption in IGF‐I treatment restored androgen levels to normal values. At the same time, the acne and oligomenorrhoea resolved. CONCLUSIONS: Overdosage of IGF‐I can lead to androgenization, a previously undescribed undesirable effect of IGF‐I. Long‐term IGF‐I treatment necessitates progressive adjustment of the IGF‐I dose to avoid overtreatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.1998.00356.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 85

Metadata

Authors
Klinger, Anin, Silbergeld, Eshet, & Laron
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1998-01
Volume
48
Issue
1
Pages
81-87
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2066888327
Cited by
85
References
3
FWCI
3.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of hyperandrogenism during treatment with insulin‐like growth factor‐I (IGF‐I) in female patients with Laron syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2265.1998.00356.x
The paper
Klinger, Anin, Silbergeld, Eshet, & Laron. (1998). Development of hyperandrogenism during treatment with insulin‐like growth factor‐I (IGF‐I) in female patients with Laron syndrome. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1998.00356.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.